Get the Stockscreener App
8.64
2.92%
-0.26
Transcode Therapeutics Inc stock is traded at $8.64, with a volume of 475.
It is down -2.92% in the last 24 hours and down -11.70% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$8.90
Open:
$8.9
24h Volume:
475
Relative Volume:
0.00
Market Cap:
$8.16M
Revenue:
-
Net Income/Loss:
$-27.13M
P/E Ratio:
-0.0357
EPS:
-242.0756
Net Cash Flow:
$-14.52M
1W Performance:
+3.35%
1M Performance:
-11.70%
6M Performance:
-41.82%
1Y Performance:
-22.47%
1-Day Range:
$8.90
$8.90
1-Week Range:
$7.88
$10.30
52-Week Range:
$6.0829
$22.03
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
8.90 | 7.53M | 0 | -27.13M | -14.52M | -242.08 |
VRTX
Vertex Pharmaceuticals Inc
|
439.91 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.91 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
845.30 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.69 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.66 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Aug Weekly: Is TransCode Therapeutics Inc showing insider buying2026 Major Catalysts & Daily Risk Controlled Trade Plans - baoquankhu1.vn
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
Geopolitics Watch: Can TransCode Therapeutics Inc sustain its profitability - baoquankhu1.vn
TransCode Therapeutics signs financing deal worth up to $20 million - MSN
Chipmakers Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averaging2026 Macro Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Big Picture: What is TransCode Therapeutics Incs P E ratio telling us2026 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
Insider Sell: Why is TransCode Therapeutics Inc stock going downEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
TransCode Therapeutics Secures New Financing to Extend Runway - The Globe and Mail
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 - Bitget
TransCode Therapeutics Secures Up to $20 Million Financing for Metastatic Cancer Trial - citybuzz -
TransCode Therapeutics Secures Up to $20 Million Flexible Financing to Advance Lead Cancer Program and Extend Runway Into 2028 - Minichart
Eightco (NASDAQ: ORBS) Represents the Biggest Public Market Exposure to OpenAI for Retail Investors - Weekly Voice
TransCode Therapeutics Secures $20M Financing - citybiz
Transcode Therapeutics Secures Up To $14 Million Standby Equity Facility and $6 Million Notes With Yorkville - TradingView — Track All Markets
TransCode Therapeutics (NASDAQ: RNAZ) lines up up to $20M in new flexible funding - Stock Titan
TransCode lands $20M to keep its cancer trial funded into 2027 - Stock Titan
Market Overview: How sensitive is TransCode Therapeutics Inc to inflationWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Form 8-KCurrent report - ADVFN
Responsive Playbooks and the RNAZ Inflection - Stock Traders Daily
RNAZ PE Ratio & Valuation, Is RNAZ Overvalued - Intellectia AI
TransCode Therapeutics, Inc. (RNAZ) Competitors - Meyka
TransCode Therapeutics Delays 2025 Annual Filing - The Globe and Mail
Bank Watch: Is TransCode Therapeutics Inc attractive for institutional investorsTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is TransCode Therapeutics Inc attractive for institutional investorsWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
RNAZ (RNAZ) delays 2025 Form 10-K after $25M preferred placement and acquisition - Stock Titan
Growth Value: Is TransCode Therapeutics Inc showing insider buying2026 Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Gap Down: Is TransCode Therapeutics Inc subject to activist investor interestAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Volume: What are analysts price targets for TransCode Therapeutics IncDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
Aug Mood: Does TransCode Therapeutics Inc have pricing power2026 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Bond Watch: Whats the outlook for TransCode Therapeutics Incs sector2026 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Understanding the Setup: (RNAZ) and Scalable Risk - Stock Traders Daily
Portfolio Update: Will TransCode Therapeutics Inc benefit from sector rotation2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
Is TransCode Therapeutics Inc undervalued by DCF analysis2026 Spike Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Breakout Zone: Should I hold or sell TransCode Therapeutics Inc now2026 Trends & Smart Money Movement Tracker - baoquankhu1.vn
Aug Chart Watch: Is TransCode Therapeutics Inc showing insider buyingWeekly Profit Summary & Momentum Based Trading Ideas - baoquankhu1.vn
The Technical Signals Behind (RNAZ) That Institutions Follow - Stock Traders Daily
RNAZ Should I Buy - Intellectia AI
How interest rate cuts could boost TransCode Therapeutics Inc. stockWeekly Profit Analysis & Safe Swing Trade Setup Alerts - Naître et grandir
Bank Watch: Is TransCode Therapeutics Inc a good ESG investmentJuly 2025 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
Aug Macro: Can TransCode Therapeutics Inc disrupt its industryJuly 2025 Chart Watch & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Weekly: Is TransCode Therapeutics Inc a speculative investmentTrend Reversal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Revista ADVFN
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits
TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal - The Globe and Mail
TransCode Therapeutics (NASDAQ: RNAZ) adds Unleash oncolytic platform in all-stock licensing deal - Stock Titan
TransCode licenses bladder cancer therapy platform from Unleash - Investing.com
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics Incenters exclusive license agreement with Unleash - marketscreener.com
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire
RNAZTransCode Therapeutics Announces Strategic Expansion of its Product Portfolio - mx.advfn.com
RNAZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.76%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):